Becker's Healthcare March 21, 2023
Bari Faye Dean

In advance of the ending of the COVID-19 public health emergency on May 11, the FDA will end some of the 72 pandemic-related guidance policies and keep some in place for an additional 180 days after the PHE ends, according to a notice in the March 13 Federal Register.

Further, the FDA said, 24 policies are expected to remain in place for the long term — with revisions that will be considered by FDA leaders during the 180-day period following the end of the PHE.

“Circumstances have changed since 2020 when FDA first began issuing guidances to support COVID-19 response efforts. For example, several COVID-19 guidances were developed to

help address supply chain disruptions. In several instances, supply chains...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: FDA, Govt Agencies, Healthcare System, Public Health / COVID
Friday Q&A: Stanford Biodesign’s Makower on expediting Medicare coverage for breakthrough devices
Paxlovid becomes 1st approved COVID-19 pill
FDA Approves Celltroin’s Yuflyma as Humira Biosimilar for 8 Disease States
First Ever Topical Gene Therapy Approved For “Butterfly Disease” Children
Withdrawals Of COVID-19 Biologics Should Prompt Us To Reimagine Our Drug Pipeline

Share This Article